Phase II Study of Thalidomide (NSC 66847) in Patients With Sarcomas of Gynecologic Origin.

Trial Profile

Phase II Study of Thalidomide (NSC 66847) in Patients With Sarcomas of Gynecologic Origin.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Thalidomide (Primary)
  • Indications Sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Aug 2006 Status change
    • 23 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top